Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy

Clinical Immunology

Volumn 137, Issue 1, 2010, Pages 41-50

  Martinez Rodriguez J E ^a   Saez Borderias A ^a,b   Munteis, E ^a   Romo, N ^a,b   Roquer, J ^a   Lopez Botet M ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

CD56; Interferon beta; LILRB1; Multiple sclerosis; Natural killer receptors

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BIOLOGICAL MARKER; CD56 ANTIGEN; GLATIRAMER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATALIZUMAB; NATURAL KILLER CELL LECTIN LIKE RECEPTOR;

ADULT; AGE; ANALYSIS; ARTICLE; ASSOCIATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERCEPTION; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGING; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD56; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INTERFERON-BETA; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR; RECEPTORS, NATURAL KILLER CELL; RECURRENCE; TIME FACTORS;

EID: 77956618482     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.06.002     Document Type: Article

References (41)

1. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
2. Munz C., Lunemann J.D., Getts M.T., Miller S.D. Antiviral immune responses: triggers of or triggered by autoimmunity?. Nat. Rev. Immunol. 2009, 9:246-258.
3. Lunemann J.D., Munz C. EBV in MS: guilty by association?. Trends Immunol. 2009, 30:243-248.
4. Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007, 61:288-299.
5. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007, 204:2899-2912.
6. Lunemann J.D., Jelcic I., Roberts S., Lutterotti A., Tackenberg B., Martin R., et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J. Exp. Med. 2008, 205:1763-1773.
7. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 2002, 195:327-333.
8. Zingoni A., Sornasse T., Cocks B.G., Tanaka Y., Santoni A., Lanier L.L. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J. Immunol. 2004, 173:3716-3724.
9. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5941-5946.
10. De Jager P.L., Rossin E., Pyne S., Tamayo P., Ottoboni L., Viglietta V., et al. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain 2008, 131:1701-1711.
11. Kastrukoff L.F., Morgan N.G., Zecchini D., White R., Petkau A.J., Satoh J., et al. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. Neurology 1999, 52:351-359.
12. Zhang B., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186:1677-1687.
13. Takahashi K., Aranami T., Endoh M., Miyake S., Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004, 127:1917-1927.
14. Xu W., Fazekas G., Hara H., Tabira T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 163:24-30.
15. Rabinovich B.A., Li J., Shannon J., Hurren R., Chalupny J., Cosman D., et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J. Immunol. 2003, 170:3572-3576.
16. Bielekova B., Howard T., Packer A.N., Richert N., Blevins G., Ohayon J., et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 2009, 66:483-489.
17. Saraste M., Irjala H., Airas L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci. 2007, 28:121-126.
18. Wynn D., Kaufman M., Montalban X., Vollmer T., Simon J., Elkins J., et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010, 9:381-390.
19. Strowig T., Brilot F., Arrey F., Bougras G., Thomas D., Muller W.A., et al. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma. PLoS Pathog. 2008, 4:e27.
20. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
21. Moretta L., Bottino C., Pende D., Vitale M., Mingari M.C., Moretta A. Different checkpoints in human NK-cell activation. Trends Immunol. 2004, 25:670-676.
22. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 2005, 5:201-214.
23. Vivier E., Anfossi N. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat. Rev. Immunol. 2004, 4:190-198.
24. Guma M., Angulo A., Vilches C., Gomez-Lozano N., Malats N., Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004, 104:3664-3671.
25. Guma M., Budt M., Saez A., Brckalo T., Hengel H., Angulo A., et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 2006, 107:3624-3631.
26. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
27. Colonna M., Navarro F., Bellon T., Llano M., Garcia P., Samaridis J., et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 1997, 186:1809-1818.
28. Perini P., Wadhwa M., Buttarello M., Meager A., Facchinetti A., Thorpe R., et al. Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients. J. Neuroimmunol. 2000, 105:91-95.
29. Poli A., Michel T., Theresine M., Andres E., Hentges F., Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009, 126:458-465.
30. Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997, 7:273-282.
31. Antrobus R.D., Khan N., Hislop A.D., Montamat-Sicotte D., Garner L.I., Rickinson A.B., et al. Virus-specific cytotoxic T lymphocytes differentially express cell-surface leukocyte immunoglobulin-like receptor-1, an inhibitory receptor for class I major histocompatibility complex molecules. J. Infect. Dis. 2005, 191:1842-1853.
32. Young N.T., Uhrberg M., Phillips J.H., Lanier L.L., Parham P. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J. Immunol. 2001, 166:3933-3941.
33. Jilek S., Schluep M., Meylan P., Vingerhoets F., Guignard L., Monney A., et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008, 131:1712-1721.
34. Anfossi N., Pascal V., Vivier E., Ugolini S. Biology of T memory type 1 cells. Immunol. Rev. 2001, 181:269-278.
35. Czesnikiewicz-Guzik M., Lee W.W., Cui D., Hiruma Y., Lamar D.L., Yang Z.Z., et al. T cell subset-specific susceptibility to aging. Clin. Immunol. 2008, 127:107-118.
36. Saverino D., Ghiotto F., Merlo A., Bruno S., Battini L., Occhino M., et al. Specific recognition of the viral protein UL18 by CD85j/LIR-1/ILT2 on CD8+ T cells mediates the non-MHC-restricted lysis of human cytomegalovirus-infected cells. J. Immunol. 2004, 172:5629-5637.
37. Monsivais-Urenda A., Nino-Moreno P., Abud-Mendoza C., Baranda L., Layseca-Espinosa E., Lopez-Botet M., et al. Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J. Autoimmun. 2007, 29:97-105.
38. Poon K., Montamat-Sicotte D., Cumberbatch N., McMichael A.J., Callan M.F. Expression of leukocyte immunoglobulin-like receptors and natural killer receptors on virus-specific CD8+ T cells during the evolution of Epstein-Barr virus-specific immune responses in vivo. Viral Immunol. 2005, 18:513-522.
39. Dalbeth N., Gundle R., Davies R.J., Lee Y.C., McMichael A.J., Callan M.F. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J. Immunol. 2004, 173:6418-6426.
40. Williams H., McAulay K., Macsween K.F., Gallacher N.J., Higgins C.D., Harrison N., et al. The immune response to primary EBV infection: a role for natural killer cells. Br. J. Haematol. 2005, 129:266-274.
41. Romagnani C., Juelke K., Falco M., Morandi B., D'Agostino A., Costa R., et al. CD56bright CD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J. Immunol. 2007, 178:4947-4955.